Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

ImpediMed stock

IPD.AX
AU000000IPD8

Price

0.06
Today +/-
+0.00
Today %
+1.74 %
P

ImpediMed stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the ImpediMed stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the ImpediMed stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the ImpediMed stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze ImpediMed's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

ImpediMed Stock Price History

DateImpediMed Price
10/1/20240.06 undefined
9/30/20240.06 undefined
9/27/20240.06 undefined
9/26/20240.06 undefined
9/25/20240.06 undefined
9/24/20240.05 undefined
9/23/20240.06 undefined
9/20/20240.05 undefined
9/19/20240.05 undefined
9/18/20240.05 undefined
9/17/20240.05 undefined
9/16/20240.05 undefined
9/13/20240.05 undefined
9/12/20240.05 undefined
9/11/20240.04 undefined
9/10/20240.04 undefined
9/9/20240.05 undefined
9/6/20240.05 undefined
9/5/20240.05 undefined
9/4/20240.05 undefined
9/3/20240.05 undefined

ImpediMed Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into ImpediMed, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by ImpediMed from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects ImpediMed’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of ImpediMed. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into ImpediMed’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing ImpediMed’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on ImpediMed’s growth potential.

ImpediMed Revenue, EBIT and net profit per share

DateImpediMed RevenueImpediMed EBITImpediMed Net Income
2028e68.58 M undefined0 undefined0 undefined
2027e50.44 M undefined0 undefined0 undefined
2026e28.8 M undefined-3.67 M undefined-4.09 M undefined
2025e16.82 M undefined-14.8 M undefined-17.88 M undefined
202410.32 M undefined-21.22 M undefined-19.79 M undefined
202311.34 M undefined-21.26 M undefined-20.52 M undefined
202210.57 M undefined-19.85 M undefined-19.87 M undefined
20218.41 M undefined-21.23 M undefined-20.71 M undefined
20205.74 M undefined-22.9 M undefined-21.38 M undefined
20194.16 M undefined-24.31 M undefined-24.12 M undefined
20183.32 M undefined-27.65 M undefined-27.37 M undefined
20176.13 M undefined-27.5 M undefined-27.57 M undefined
20165.95 M undefined-23.66 M undefined-25.98 M undefined
20154.93 M undefined-14.8 M undefined-14.8 M undefined
20143.58 M undefined-7.95 M undefined-7.94 M undefined
20132.93 M undefined-8.42 M undefined-8.46 M undefined
20123.18 M undefined-12.71 M undefined-12.34 M undefined
20114.17 M undefined-11.91 M undefined-14.82 M undefined
20103.81 M undefined-11.34 M undefined-11.4 M undefined
20093.27 M undefined-13.68 M undefined-14.03 M undefined
20082.99 M undefined-8.06 M undefined-9.76 M undefined
20071.94 M undefined-7 M undefined-10.13 M undefined
20061.08 M undefined-4.94 M undefined-7.58 M undefined
2005440,000 undefined-3.23 M undefined-3.19 M undefined

ImpediMed Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (B)DOCUMENTS
200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e2028e
0112334323456345810111016285068
---100.0050.00-33.33-25.00-33.3350.0033.3325.0020.00-50.0033.3325.0060.0025.0010.00-9.0960.0075.0078.5736.00
--100.00100.0033.3366.6750.0033.3350.0066.6775.0080.0066.6766.6750.0080.0075.0080.0081.8290.00----
001212211234422468990000
-3-4-7-8-13-11-11-12-8-7-14-23-27-27-24-22-21-19-21-21-14-300
--400.00-700.00-400.00-433.33-366.67-275.00-400.00-400.00-233.33-350.00-460.00-450.00-900.00-600.00-440.00-262.50-190.00-190.91-210.00-87.50-10.71--
-3-7-10-9-14-11-14-12-8-7-14-25-27-27-24-21-20-19-20-19-17-400
-133.3342.86-10.0055.56-21.4327.27-14.29-33.33-12.50100.0078.578.00--11.11-12.50-4.76-5.005.26-5.00-10.53-76.47--
0.080.080.080.070.090.120.150.170.190.20.280.340.390.40.40.61.21.681.82.020000
------------------------
Details

Keystats

ⓘ

Revenue and Growth

The ImpediMed Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the ImpediMed is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (k)LONG-T. REC. (k)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (k)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
200720082009201020112012201320142015201620172018201920202021202220232024
                                   
1.768.456.6318.7917.914.517.3210.8132.5882.2554.8831.3511.3319.6619.6840.7345.7124.63
0.750.670.680.550.540.560.410.440.620.941.231.071.251.662.782.752.632.19
00.20.060.220.130.210.040.010.012.572.583.042.742.861.831.631.761.01
0.421.240.951.381.281.661.331.131.641.381.471.811.120.860.370.930.810.76
0.850.190.150.260.370.330.340.350.270.511.10.340.540.4110.621.030.86
3.7810.758.4721.220.2217.279.4412.7435.1287.6561.2637.616.9725.4525.6546.6651.9429.46
0.20.40.670.540.430.40.330.20.30.40.520.370.191.021.030.421.951.45
9040302020206050620095457773757854
00000000000000018000
0.191.291.550.920.370.070.050.040.040.040.051.062.793.895.048.7412.0413.31
02.042.252.121.711.781.991.922.372.442.362.452.582.642.422.632.732.72
0012012070700031481580000000
0.483.774.623.722.62.342.432.212.82.923.093.975.617.618.5612.0416.817.53
4.2614.5213.0924.9222.8219.6111.8714.9537.9290.5764.3441.5722.5833.0634.2158.768.7446.99
                                   
11.1550.8161.4884.5698106.1106.1116.59147.35218.81219.49219.75219.73250.56267.27307.56336.09336.15
000000000000000000
-28.94-38.51-51.42-62.33-76.72-88.3-95.51-103.01-116.01-139.47-164.46-188.57-209.85-228.94-246.62-263.49-283.25-303.72
0000-0.61-0.50-0.053.495.923.764.635.95.744.866.978.058.32
000000000000000000
-17.7912.310.0622.2320.6717.310.5913.5334.8485.2558.835.815.7927.3625.5151.0460.8840.74
0.981.161.591.611.191.550.640.81.131.832.141.812.091.911.32.641.361.1
00.150.050.140.740.620.50.511.643.263.233.64.032.225.563.453.11.67
0.320.490.960.780.040.030.050.040.20.110.090.260.550.620.960.991.091.56
20.5500000000000000000
806000000000000364315170300333
21.931.862.62.531.972.21.191.352.985.25.475.666.665.118.137.245.854.66
0.060000000000000.510.1601.150.81
000000000000000000
5035044015015010080901041157710213587398413864776
0.110.350.440.150.150.10.080.090.10.120.080.10.140.590.560.412.011.59
22.042.213.042.682.122.31.271.443.085.325.555.776.85.78.697.667.866.24
4.2514.5113.124.9122.7919.611.8614.9737.9290.5764.3441.5722.5833.0634.258.768.7446.99
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of ImpediMed provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand ImpediMed's financial health and stability.

Assets

ImpediMed's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that ImpediMed must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of ImpediMed after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into ImpediMed's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (k)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20072008200920102011201220132014201520162017201820192020202120222023
00000000000000-20-19-20
00000000000000000
00000000000000000
01,0000001,0001,0000000-16,000-15,000-17,000-13,000-18,000-19,000
00000000000000330
00000000000000000
00000000000000000
-6-7-11-10-11-11-7-6-10-22-25-23-19-19-13-15-18
0-1000000000-1-2-2-2-5-6
-1-1000000000-1-1-2-2-5-6
-10000000000000000
00000000000000000
80000000000000000
2181124148011327500033164230
10151023138010307100030163927
--1.00--1.00-----2.00-3.00----2.00--2.00-1.00
00000000000000000
-4-2-141-12-16-15-31027-53-30-2460246
-6.16-9.15-12.56-10.47-11.3-11.89-7.72-6.83-10.89-22.53-25.93-24.67-21.81-21.38-15.72-20.89-24.09
00000000000000000

ImpediMed stock margins

The ImpediMed margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ImpediMed. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ImpediMed.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the ImpediMed's sales revenue. A higher gross margin percentage indicates that the ImpediMed retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the ImpediMed's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the ImpediMed's total revenue generated. When comparing the revenue margin year over year, investors can gauge the ImpediMed's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the ImpediMed. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the ImpediMed's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

ImpediMed Margin History

ImpediMed Gross marginImpediMed Profit marginImpediMed EBIT marginImpediMed Profit margin
2028e87.27 %0 %0 %
2027e87.27 %0 %0 %
2026e87.27 %-12.74 %-14.19 %
2025e87.27 %-87.99 %-106.32 %
202487.27 %-205.67 %-191.78 %
202386.37 %-187.39 %-180.9 %
202283.83 %-187.84 %-188.09 %
202180.95 %-252.46 %-246.24 %
202070.77 %-398.95 %-372.36 %
201969.87 %-584.94 %-580.44 %
201870.58 %-833.36 %-824.95 %
201775.72 %-448.44 %-449.55 %
201673.38 %-397.85 %-436.86 %
201573.13 %-300.45 %-300.32 %
201459.78 %-222.07 %-221.79 %
201359.73 %-287.37 %-288.74 %
201260.38 %-399.69 %-388.05 %
201160.43 %-285.61 %-355.4 %
201057.74 %-297.64 %-299.21 %
200955.35 %-418.35 %-429.05 %
200876.92 %-269.57 %-326.42 %
200767.53 %-360.82 %-522.16 %
200650.93 %-457.41 %-701.85 %
200563.64 %-734.09 %-725 %

ImpediMed Stock Sales Revenue, EBIT, Earnings per Share

The ImpediMed earnings per share therefore indicates how much revenue ImpediMed has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue ImpediMed earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates ImpediMed's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of ImpediMed’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating ImpediMed's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

ImpediMed Revenue, EBIT and net profit per share

DateImpediMed Sales per ShareImpediMed EBIT per shareImpediMed Earnings per Share
2028e0.03 undefined0 undefined0 undefined
2027e0.02 undefined0 undefined0 undefined
2026e0.01 undefined0 undefined-0 undefined
2025e0.01 undefined0 undefined-0.01 undefined
20240.01 undefined-0.01 undefined-0.01 undefined
20230.01 undefined-0.01 undefined-0.01 undefined
20220.01 undefined-0.01 undefined-0.01 undefined
20210.01 undefined-0.02 undefined-0.02 undefined
20200.01 undefined-0.04 undefined-0.04 undefined
20190.01 undefined-0.06 undefined-0.06 undefined
20180.01 undefined-0.07 undefined-0.07 undefined
20170.02 undefined-0.07 undefined-0.07 undefined
20160.02 undefined-0.07 undefined-0.08 undefined
20150.02 undefined-0.05 undefined-0.05 undefined
20140.02 undefined-0.04 undefined-0.04 undefined
20130.02 undefined-0.04 undefined-0.04 undefined
20120.02 undefined-0.08 undefined-0.07 undefined
20110.03 undefined-0.08 undefined-0.1 undefined
20100.03 undefined-0.1 undefined-0.1 undefined
20090.04 undefined-0.15 undefined-0.15 undefined
20080.04 undefined-0.12 undefined-0.14 undefined
20070.02 undefined-0.08 undefined-0.12 undefined
20060.01 undefined-0.06 undefined-0.09 undefined
20050.01 undefined-0.04 undefined-0.04 undefined

ImpediMed business model

ImpediMed Ltd is an Australian company specializing in medical devices and technologies. They were founded in 1999 and have their headquarters in Brisbane, Australia. The company is a leading provider of bioimpedance measurement devices for the diagnosis, monitoring, and treatment of lymphatic, cardiac, and other medical conditions. They have a wide range of products used in various medical fields, including oncology, lymphology, and cardiology. Their main business model is based on the development and marketing of their bioimpedance measurement devices. They also provide training and support for medical personnel to optimize the use of their devices. ImpediMed specializes in the diagnosis and treatment of lymphedema in the oncology sector, particularly using their highly precise L-Dex® device. They also analyze body composition in the cardiology sector to determine the risk of heart diseases and develop personalized treatment approaches. In recent years, ImpediMed has expanded into the European market, particularly in lymphedema diagnosis and treatment. Overall, ImpediMed Ltd is an innovative company that focuses on medical devices and technologies for the diagnosis and monitoring of cardiac and lymphatic diseases. They provide important diagnostic capabilities to medical professionals and continue to focus on growth and expansion. ImpediMed is one of the most popular companies on Eulerpool.com.

ImpediMed SWOT Analysis

Strengths

ImpediMed Ltd possesses a unique technology that enables the non-invasive assessment of physiological conditions through bioimpedance spectroscopy. This technology has allowed the development of innovative products that have the potential to revolutionize various medical fields.

ImpediMed Ltd holds a robust intellectual property portfolio, including patents and trademarks, which provide competitive advantages and barriers to entry for potential competitors. This strengthens the company's position in the market and enhances its ability to protect its innovative technology.

ImpediMed Ltd has successfully established a strong market presence by partnering with healthcare institutions and professionals worldwide. Its products have gained recognition for their accuracy and effectiveness, contributing to the company's reputation and brand value.

Weaknesses

ImpediMed Ltd heavily relies on strategic partnerships for distribution, marketing, and sales of its products. This dependency imposes a level of vulnerability on the company, as any disruptions or termination of partnerships could adversely impact its revenue and growth prospects.

While ImpediMed Ltd has made significant progress in expanding its market presence, there is still room for improvement in terms of market penetration. The company needs to further strengthen its marketing efforts and expand its customer base to drive greater adoption of its products.

Opportunities

The increasing preference for non-invasive medical technologies presents a significant opportunity for ImpediMed Ltd. With its unique bioimpedance spectroscopy technology, the company is well-positioned to meet the rising demand for accurate and non-invasive physiological assessments across various medical disciplines.

ImpediMed Ltd has the potential to expand its product offerings into new markets beyond its current focus areas. By identifying and targeting untapped markets, the company can diversify its revenue streams and reduce its dependence on specific regions or segments, thereby enhancing its growth prospects.

Threats

ImpediMed Ltd operates in a highly competitive industry, facing competition from both established medical device companies and emerging startups. The presence of numerous competitors increases the risk of pricing pressures and the need for continuous innovation to differentiate the company's products from others in the market.

The medical device industry is subject to strict regulatory requirements, which can pose challenges for product development, approvals, and commercialization. Additionally, reimbursement policies and limitations imposed by healthcare payers may impact the adoption and utilization of ImpediMed Ltd's products, potentially hindering market growth.

ImpediMed Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

ImpediMed historical P/E ratio, EBIT multiple, and P/S ratio

ImpediMed shares outstanding

The number of shares was ImpediMed in 2023 — This indicates how many shares 1.8 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue ImpediMed earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates ImpediMed's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of ImpediMed’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating ImpediMed's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for ImpediMed.

ImpediMed latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.01 -0.01  (-47.54 %)2024 Q4
12/31/2023-0.01 -0  (80.39 %)2024 Q2
6/30/2023-0.01 -0.01  (1.96 %)2023 Q4
12/31/2022-0.01 -0.01  (1.64 %)2023 Q2
6/30/2022-0.01 0  (100 %)2022 Q4
12/31/2021-0.01 -0.01  (0.99 %)2022 Q2
6/30/2019-0.03 -0.03  (7.5 %)2019 Q4
1

Eulerpool ESG Scorecard© for the ImpediMed stock

Eulerpool World ESG Rating (EESG©)

37/ 100

🌱 Environment

10

👫 Social

59

🏛️ Governance

41

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees48.684
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

ImpediMed shareholders

%
Name
Stocks
Change
Date
8.61004 % Paradice Investment Management Pty. Ltd.174,188,82826,281,9173/8/2024
5.69944 % Australian Ethical Investment Ltd.115,304,879-7,208,9293/8/2024
1.11171 % MBA Investments Pty. Ltd.22,490,99009/28/2023
1.05105 % Jones (Hamish Alexander)21,263,70521,263,7057/31/2023
1.04296 % Brown (Gregory Wayne)21,100,000-18,165,0307/31/2023
1.01065 % Dior (Stephen Mahnken)20,446,36320,446,3637/28/2023
1.00026 % Henderson International Pty. Ltd.20,236,16709/28/2023
0.93916 % Sunlora Pty. Ltd.19,000,00009/28/2023
0.86362 % Apex Investment Management Pty. Ltd.17,471,778230,7707/31/2023
0.79143 % Pakasoluto Pty. Ltd.16,011,42209/28/2023
1
2
3
4

Most common questions regarding ImpediMed

What values and corporate philosophy does ImpediMed represent?

ImpediMed Ltd represents values of innovation, integrity, and dedication to improving healthcare outcomes. The company's corporate philosophy focuses on providing advanced and accurate medical devices and solutions for the assessment and monitoring of body composition and fluid status. ImpediMed is committed to delivering products that assist healthcare professionals in making informed decisions for better patient management. With a strong emphasis on research and development, ImpediMed continuously strives to revolutionize the field of bioimpedance spectroscopy, ensuring accurate and non-invasive measurements. By placing a significant emphasis on technological advancements, ImpediMed Ltd aims to transform patient care and improve overall health outcomes.

In which countries and regions is ImpediMed primarily present?

ImpediMed Ltd is primarily present in several countries and regions worldwide. The company has a global presence with a focus on key markets including the United States, Australia, and Europe. ImpediMed operates in the healthcare industry, providing medical devices and solutions for the management and monitoring of lymphedema, heart failure, and body composition. With its innovative technologies and strong market penetration, ImpediMed continues to expand its presence and deliver its products to healthcare professionals and patients worldwide.

What significant milestones has the company ImpediMed achieved?

ImpediMed Ltd, a leading medical technology company, has accomplished several significant milestones throughout its journey. The company successfully developed and commercialized its innovative bioimpedance spectroscopy technology, the L-Dex System. This revolutionary product enables early detection of lymphedema, a condition commonly associated with cancer treatment. ImpediMed also received FDA approval for its product, marking a crucial milestone in expanding its market reach. Furthermore, the company has made notable progress through strategic collaborations with prestigious medical institutions and key partnerships with renowned healthcare organizations. ImpediMed's commitment to advancing patient care, combined with its continuous technological advancements, showcases its substantial achievements in the medical technology industry.

What is the history and background of the company ImpediMed?

ImpediMed Ltd is an Australian-based medical technology company founded in 1999. The company specializes in the development and commercialization of bioimpedance spectroscopy (BIS) devices for non-invasive fluid management. ImpediMed's technology has applications in the areas of lymphedema management, early detection of secondary lymphedema, and monitoring of body composition in clinical and research settings. With a focus on improving patient outcomes, ImpediMed has established a strong reputation in the medical field. As a leading provider of BIS technology, ImpediMed continues to innovate and make advancements in the field of medical diagnostics and patient care.

Who are the main competitors of ImpediMed in the market?

The main competitors of ImpediMed Ltd in the market are [competitor names].

In which industries is ImpediMed primarily active?

ImpediMed Ltd is primarily active in the healthcare industry.

What is the business model of ImpediMed?

The business model of ImpediMed Ltd focuses on developing and commercializing medical devices for measuring and monitoring fluid status and tissue impedance. ImpediMed specializes in bioimpedance spectroscopy (BIS) and bioimpedance analysis (BIA) technologies, which are used in various medical fields such as lymphedema, heart failure, and chronic kidney disease. The company's products provide non-invasive measurements to help clinicians assess fluid status and tissue composition, aiding in the early detection and management of various medical conditions. ImpediMed's innovative devices and solutions contribute to improved patient outcomes and cost-effective healthcare interventions.

What is the P/E ratio of ImpediMed 2024?

The ImpediMed P/E ratio is -5.93.

What is the P/S ratio of ImpediMed 2024?

The ImpediMed P/S ratio is 11.36.

What is the AlleAktien quality score of ImpediMed?

The AlleAktien quality score for ImpediMed is 6/10.

What is the revenue of ImpediMed 2024?

The ImpediMed revenue is 10.32 M AUD.

How high is the profit of ImpediMed 2024?

The ImpediMed profit is -19.79 M AUD.

What is the business model of ImpediMed

ImpediMed Ltd is a global company specializing in the development of medical devices and solutions for measuring lymphedema and other fluid accumulation in the body. The company was founded in 1999 and is headquartered in Brisbane, Australia. ImpediMed is divided into two main business segments - ImpediMed and Sozo. ImpediMed specializes in the development of bioimpedance devices, while Sozo specializes in the measurement of body fluids by combining bioimpedance with other technologies such as optical imaging and sonography. Sozo specifically addresses data-driven clinical problems by providing doctors and nurses with an objective, automated method for measuring edema. ImpediMed's bioimpedance technology is mainly used for monitoring edema and other conditions caused by irregular fluid accumulation. The device measures the electrical resistance in the tissue, allowing for an accurate determination of extracellular fluid, intracellular fluid, and body fat percentage. ImpediMed's Sozo system combines bioimpedance with other technologies. It provides accurate measurement of extracellular fluid, which is essential for the diagnosis, monitoring, and therapy management of various diseases, including lymphedema. ImpediMed also offers training on specific diseases for doctors and nursing staff. ImpediMed specializes in developing medical products for the field of oncology and lymphedema patients. The company also offers specialized post-care for oncology patients by supporting monitoring for edema, swelling, and body fluids. ImpediMed has established itself as a leading provider of edema monitoring solutions and operates in Europe, Asia, North America, and Australia. The company is committed to providing its customers with reliable and accurate diagnoses to enable a good quality of life for people suffering from various edema conditions. It collaborates with specialized physicians in various medical fields. Overall, ImpediMed is a successful company that has found a niche in the medical industry with its bioimpedance technology. The variety of products and solutions it offers, along with collaborations with specialized physicians, have contributed to its establishment as a leading player in edema monitoring in a short period of time.

What is the ImpediMed dividend?

ImpediMed pays a dividend of 0 AUD distributed over payouts per year.

How often does ImpediMed pay dividends?

The dividend cannot currently be calculated for ImpediMed or the company does not pay out a dividend.

What is the ImpediMed ISIN?

The ISIN of ImpediMed is AU000000IPD8.

What is the ImpediMed ticker?

The ticker of ImpediMed is IPD.AX.

How much dividend does ImpediMed pay?

Over the past 12 months, ImpediMed paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ImpediMed is expected to pay a dividend of 0 AUD.

What is the dividend yield of ImpediMed?

The current dividend yield of ImpediMed is .

When does ImpediMed pay dividends?

ImpediMed pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ImpediMed?

ImpediMed paid dividends every year for the past 0 years.

What is the dividend of ImpediMed?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is ImpediMed located?

ImpediMed is assigned to the 'Health' sector.

Wann musste ich die Aktien von ImpediMed kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ImpediMed from 10/2/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did ImpediMed pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of ImpediMed in the year 2023?

In the year 2023, ImpediMed distributed 0 AUD as dividends.

In which currency does ImpediMed pay out the dividend?

The dividends of ImpediMed are distributed in AUD.

All fundamentals about ImpediMed

Our stock analysis for ImpediMed Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ImpediMed Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.